Work

Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study

Year: 2015

Type: article

Study design: Clinical Trial

Source: The Lancet Infectious Diseases

DOI: 10.1016/s1473-3099(15)70060-5

Authors: Dianne Carey, Rebekah Puls, Janaki Amin, Marcelo Losso, Praphan Phanupak, Sharne Foulkes, Lerato Mohapi, Brenda Crabtree-Ramirez, Heiko Jessen, Suresh Kumar, Alan Winston, Man-Po Lee, Waldo Belloso, David A Cooper, Sean Emery

Language: English

Topic: HIV/AIDS drug development and treatment

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Bill and Melinda Gates Foundation, Australian Government, Mylan, Department of Health and Ageing, Australian Government, University of New South Wales

Award: G1792339240

OpenAlex ID: W2184719281

FWCI: 14.03

Cites: 20

Cited by: 113

Related to: 10